Synthesis and structure–activity relationships of piperidine-based melanin-concentrating hormone receptor 1 antagonists
摘要:
Isosteric replacement of the urea group of lead compound 1 led to novel substituted piperidine phenylamide analogues. SAR on the electron-induced effects of various linkers as well as substituents on the phenyl rings and the piperidine nitrogen has been investigated. Many single-digit nanomolar MCH R1 antagonists have been identified from this series. (c) 2006 Elsevier Ltd. All rights reserved.
[EN] PYRAZOLOPYRAZINES ACTING ON CANCERS VIA INHIBITION OF CDK12<br/>[FR] PYRAZOLOPYRAZINES AGISSANT SUR DES CANCERS PAR INHIBITION DE CDK12
申请人:BAYER AG
公开号:WO2021176049A1
公开(公告)日:2021-09-10
The present invention provides compounds of general formula (I) in which X, R1, R2 and R3 are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of hyperproliferative disorders such as cancer disorders, as a sole agent or in combination with other active ingredients.
[EN] NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS UTILES EN TANT QU'INHIBITEURS DE S100
申请人:ACTIVE BIOTECH AB
公开号:WO2015177367A1
公开(公告)日:2015-11-26
A compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.
[EN] 5-AMINO-2-(1-HYDROXY-ETHYL)-TETRAHYDROPYRAN DERIVATIVES<br/>[FR] DÉRIVÉS DE 5-AMINO-2-(1-HYDROXYÉTHYL)TÉTRAHYDROPYRANE
申请人:ACTELION PHARMACEUTICALS LTD
公开号:WO2010067332A1
公开(公告)日:2010-06-17
The invention relates to antibacterial compounds of formula I wherein R1 represents alkoxy (notably methoxy); R2 represents H or F; each of R3, R4, R5 and R6 represents independently H or D; V represents CH and W represents CH or N or V represents N and W represents CH; Y represents CH or N; Z represents O, S or CH2; and A represents CH2, CH2CH2 or CD2CD2; and salts of such compounds.
The invention relates to antibacterial compounds of formula I
wherein
R
1
represents alkoxy (notably methoxy);
R
2
represents H or F;
each of R
3
, R
4
, R
5
and R
6
represents independently H or D;
V represents CH and W represents CH or N, or V represents N and W represents CH;
Y represents CH or N;
Z represents O, S or CH
2
; and
A represents CH
2
, CH
2
CH
2
or CD
2
CD
2
;
and salts of such compounds.